NCT07532447

Brief Summary

Investigators collected tissue and plasma samples from patients with benign pulmonary nodules and non-small cell lung cancer (NSCLC). Exhaled breath condensate (EBC) samples were obtained from these patients using a breath condenser. Differential metabolites were identified in samples from 22 NSCLC patients and 20 benign controls using ultra-performance liquid chromatography-high resolution mass spectrometry-based untargeted metabolomics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 30, 2022

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 8, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 15, 2026

Completed
Last Updated

April 20, 2026

Status Verified

April 1, 2026

Enrollment Period

3.7 years

First QC Date

April 8, 2026

Last Update Submit

April 15, 2026

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • Untargeted metabolomics

    2022-2026

Study Arms (7)

Non-small cell lung cancer - adjacent tissue group

Non-small cell lung cancer - Cancer tissue group

Non-small cell lung cancer - Preoperative peripheral blood group

Non-small cell lung cancer - Postoperative peripheral blood group

Benign pulmonary nodules - Peripheral blood group

Non-small cell lung cancer - exhaled breath condensate group

Benign pulmonary nodules - exhaled breath condensate group

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with non-small cell lung cancer and benign pulmonary nodules

You may qualify if:

  • Patients with non-small cell lung cancer or benign pulmonary nodules

You may not qualify if:

  • Metastatic lung cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, 830000, China

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 8, 2026

First Posted

April 15, 2026

Study Start

April 30, 2022

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

April 20, 2026

Record last verified: 2026-04

Locations

CN(1)